Fortrea Names Interim CFO Amid Ongoing Legal Dispute
I'm LongbridgeAI, I can summarize articles.Fortrea Holdings appointed David Smith as interim CFO following a Delaware Court order restraining former CFO Jason Knoblauch due to litigation. Amid this leadership change, Fortrea reported Q2 2026 revenue of $678.2 million and raised full-year guidance, targeting revenue between $2.62 billion and $2.69 billion. The company also highlighted improved adjusted EBITDA and a strong backlog, signaling confidence in its financial performance despite the executive transition.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Fortrea Holdings Inc. ( (FTRE) ) just unveiled an announcement.
On July 27, 2026, Fortrea’s board appointed current director David Smith as interim chief financial officer, following a July 25, 2026 Delaware Court order temporarily restraining newly hired CFO Jason Knoblauch from serving due to litigation brought by his former employer. Smith, a veteran pharmaceutical finance executive and former Charles River Laboratories CFO, will remain on the board and receive a monthly salary and restricted stock units under an at‑will offer letter.
Knoblauch, who became CFO on July 6, 2026, was placed on paid leave and is not expected to perform CFO responsibilities, though his compensation package remains intact during the court‑ordered absence. The move ensures continuity in Fortrea’s financial leadership amid legal uncertainty, with Smith’s extensive industry experience likely to reassure investors as the company pursues its strategic and financial objectives.
Fortrea also reported second‑quarter 2026 revenue of $678.2 million and a GAAP net loss of $13.2 million, showing improved profitability versus a year earlier when results were burdened by a large goodwill impairment. Adjusted EBITDA rose to $58.7 million and backlog reached $7.8 billion, supported by a book‑to‑bill ratio of 1.06x, marking a fourth consecutive quarter above 1.0x.
For the first half of 2026, revenue totaled $1.31 billion with a GAAP net loss of $36.8 million, while adjusted net income more than doubled year‑on‑year and adjusted EBITDA increased to $105.7 million, underscoring strengthening underlying performance. Reflecting this momentum, Fortrea raised its full‑year 2026 guidance, targeting revenue between $2.62 billion and $2.69 billion and adjusted EBITDA between $205 million and $220 million, signaling confidence in its commercial execution and margin expansion efforts.
The most recent analyst rating on (FTRE) stock is a Hold
with a $16.00 price target.
To see the full list of analyst forecasts on Fortrea Holdings Inc. stock,
see the FTRE Stock Forecast page.
Spark’s Take on FTRE Stock
According to Spark, TipRanks’ AI Analyst, FTRE is a Neutral.
FTRE scores in the mid-range primarily due to weak recent operating performance (sharp TTM revenue decline, margin compression, and ongoing losses) partially offset by stronger cash generation and currently conservative leverage. The stock’s technical setup is positive with price above all major moving averages, while valuation is difficult to support given negative earnings and no dividend. Earnings-call commentary is moderately supportive on reiterated guidance, improving bookings/backlog, and cost savings, but near-term revenue and cash-flow pressures temper the upside.
To see Spark’s full report on FTRE stock,
click here.
More about Fortrea Holdings Inc.
Fortrea Holdings Inc., listed on Nasdaq as FTRE, is a leading global contract research organization providing clinical development solutions to the life sciences industry. It partners with biopharmaceutical, biotechnology, medical device and diagnostic companies to manage phase I–IV clinical trials, clinical pharmacology and consulting services, leveraging three decades of experience across more than 20 therapeutic areas.
The company operates in about 100 countries with a strong investigator site network, positioning it as a scaled but agile provider focused on advancing innovative therapies to patients. Its market focus is on supporting emerging and large healthcare innovators with scientifically rigorous, data-driven services that streamline drug development and enhance commercial and operational execution.
Average Trading Volume: 1,456,154
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.82B
For an in-depth examination of FTRE stock, go to TipRanks’ Overview page.